Skip to content

Impact of Readability Improvements on the Comprehension of Written Information Given to Clinical Trial Patients: a RCT

Multicenter RCT to Assess the Impact of Improvements in Lexico-syntactic Readability and Good Practice in Writing on the Comprehension of Written Information Given to Patients Participating in Clinical Trials.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00908557
Acronym
LISYCOM
Enrollment
400
Registered
2009-05-27
Start date
2009-04-30
Completion date
2014-03-31
Last updated
2014-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comprehension

Keywords

Lexicosyntactic readability improvement, phase II/III trials, ethic, Informed consent

Brief summary

The principle objective of this randomised controlled trial is to assess whether an improvement in lexico-syntactic readability combined with adherence to French recommendations for good practice in writing the Information and Consent Form (ICF) given to patients participating in clinical trials, increases their understanding of the information compared to conventional written information, in real (not simulated) conditions.

Detailed description

The quality of written information given to people participating in clinical trials is essential as by law all volunteers have to be informed of a certain number of key elements. Those elements that are necessary to understanding and making a decision as to whether to participate in the trial are presented to the volunteer in the information and consent document (ICD). Many terms used in the ICD are of necessity medical terms and sometimes difficult to understand for the person who may participate in the study. Several factors are involved when a reader receives a text, and one of the difficulties of intelligibility can be the lexico-syntactic readability. The lexico-syntactic readability is the only element of intelligibility that can be readily quantified, using the Flesch-Kincaid index. It is also an element that can be very easily modified without changing the sense of the information. In the QuIP-3 study, which we performed in 2003, it appeared that the lexico-syntactic readability of ICF is very low, lower than that of texts used in university level classics examinations. Furthermore, there is no correlation between the density of information and readability (QuIP-5 study). It seems to be necessary to assess the understanding of those participating in clinical trials in terms of logical and cognitive intelligibility (representativeness and interpretability of the information and consent forms). Indeed, a text may be unreadable according to the Flesch score, in lexico-syntactic terms, but perfectly understood and interpreted. As no questionnaire had been validated in French, we validated the Questionnaire d'Evaluation de la Compréhension de l'Information Ecrite par les Malades or QECIEM (Questionnaire measuring patient comprehension of written information) (QuIP-4). This questionnaire can be used to measure both objective and subjective general understanding by a patient to be included in a therapeutic study, irrespective of the pathology.

Interventions

OTHERreadability improvement and good practice redaction

improvement using Flesch readability index and good practice in redaction of informed consent documents.

OTHERControl

information based on the classic informed consent document

Sponsors

Clinical Research Center of Grenoble
CollaboratorUNKNOWN
Clinical Research Center of Strasbourg
CollaboratorUNKNOWN
Hôpital Necker-Enfants Malades
CollaboratorOTHER
Clinical Research Center of Lyon
CollaboratorUNKNOWN
Clinical Research Center of Bichat, Paris
CollaboratorUNKNOWN
Clinical Research Center of Saint-Etienne
CollaboratorUNKNOWN
Clinical Research Center - biotherapy center of Saint-Louis, Paris
CollaboratorUNKNOWN
Clinical Research Center of Clermont-Ferrand
CollaboratorUNKNOWN
Clinical Research Center of Reunion island
CollaboratorUNKNOWN
Clinical Research Center - Biotherapy center of Nantes
CollaboratorUNKNOWN
CIC 1417 Cochin-Pasteur
CollaboratorOTHER
Pharmacology unit of Créteil
CollaboratorUNKNOWN
Clinical Research Center, Toulouse
CollaboratorOTHER
University Hospital, Grenoble
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subject considered suitable to participate in one of the clinical trials selected for the LISYCOM study * Age \> 18 years

Exclusion criteria

* Illiteracy or inability to read French * Neurological deficiency making reading impossible (attention disorders, aphasy, etc) * Refusal to participate

Design outcomes

Primary

MeasureTime frame
Sub-score in part A (objective comprehension) of the QECIEM questionnaire of comprehension.24 hours

Secondary

MeasureTime frame
Sub-scores in part B (subjective comprehension) of questionnaire of comprehension.24 hours
Adhesion to proposed clinical trial protocolsend of the study or end of Lisycom
Impact of complementary oral information on the QECIEM scores24 hours
Total score in the QECIEM questionnaire of comprehension.24 hours
Number of refusals to sign informed consent form for the proposed trial.end of the study or end of Lisycom
Score of the QECIEMc1 year
Subjective evaluation of readability by the investigatorbegin of the study or begin of Lisycom

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026